Lentiviruses (LV) and adeno-associated viruses (AAV) are both commonly used viral vectors with different infection characteristics. Among these, AAVs are currently the most widely used delivery vectors in gene transduction and gene therapy due to their advantages, which include good tissue specificity, low immunogenicity, and high safety. However, lentiviral vectors (LVV) are the most commonly used for cell therapy applications, such as CAR-T cell construction, and have been widely applied in scientific and clinical research due to their wide host range, stable expression of target gene, and high infection efficiency of mammalian cells.
Cyagen provides lentivirus (LV) and adeno-associated virus (AAV) packaging services with integrated quality evaluations that ensure the reliability of virus packaging quality in terms of virus titer and purity. These lentiviral vectors (LVV) and adeno-associated viral vectors are widely used in the construction of various cell models, in vivo injection of living animals, gene therapy, and other research fields. Our additional in vivo and in vitro model development and phenotypic evaluation services enable us to serve as a comprehensive research solution provider for cell and gene therapy studies worldwide.
| System | Guaranteed Yield | Promotion Price (USD/Strain) | Turnaround Time | Ordering |
|---|---|---|---|---|
| Over-expression | ≥1E+8 TU (Titer≥ 1E+8 TU/ml) |
|
As fast as 3 weeks | |
| ≥1E+9 TU (Titer≥ 1E+9 TU/ml) |
|
|||
| Interference (3 shRNA) | ≥1E+8 TU (Titer≥ 1E+8 TU/ml) |
|
||
| ≥1E+9 TU (Titer≥ 1E+9 TU/ml) |
|
|||
| Knockout | ≥1E+8 TU (Titer≥ 1E+8 TU/ml) |
|
| Serotypes | Guaranteed Yield | Promotion Price (USD/Strain) | Turnaround Time | Ordering |
|---|---|---|---|---|
| Normal-yield AAV Serotypes | 1E+12GC (Titer≥ 5E+12GC/ml) |
|
As fast as 3 weeks | |
| 2E+12GC (Titer≥ 5E+12GC/ml) |
|
|||
| 5E+12GC (Titer≥ 1E+13GC/ml) |
|
|||
| 1E+13GC (Titer≥ 1E+13GC/ml) |
|
|||
| 2E+13GC (Titer≥ 1E+13GC/ml) |
|
|||
| 5E+13GC (Titer≥ 1E+13GC/ml) |
|
|||
| ≥1E+14GC (Titer≥ 1E+13GC/ml) | Request Quote | |||
| Low-yield AAV Serotypes (AAV2/4/6//i.e/Anc80/DJ8) | 1E+12GC (Titer≥ 5E+12GC/ml) |
|
||
| 2E+12GC (Titer≥ 5E+12GC/ml) |
|
|||
| 5E+12GC (Titer≥ 1E+13GC/ml) |
|
|||
| 1E+13GC (Titer≥ 1E+13GC/ml) |
|
|||
| 2E+13GC (Titer≥ 1E+13GC/ml |
|
|||
| ≥5E+13GC (Titer≥ 1E+13GC/ml) | Request Quote |
GC = genome copies (physical titer)
- First-time customers can enjoy lower discounts, contact us for more details!
- The estimated turnaround is the time from production initiation to project completion. Turnaround does not include wait time for any customer-supplied materials (e.g. template DNA or viral vectors) or transit time for shipping final deliverables to the customer.
800-921-8930 | 
Lentiviral Titer via Flow Cytometry - CD19 Antigen
Bioactivity Measurements of AAV Vectors
The lentiviral purification solution expressing CD19 antigen was diluted in four gradients (0.01, 0.1, 1, 10 μL) and added to the same number of 293T cells separately. After 72 hours, the positive rate of 293T cells was detected by flow cytometry. The percentage of virus-infected 293T cells to the total number of cells), and then calculate the transduction titer of the lentivirus according to the following formula: Titer= (A+10*B)*N*103/ (2*V) Tu/ml
What is the difference between AAV and LV viral vectors?
| Project | AAV | LV |
|---|---|---|
| Particle diameter | 20-30nm | 80-100nm |
| Genome | 4.7kb single-stranded DNA or 2.4kb double-stranded DNA | 9.3 kb double-stranded RNA |
| Capacity | ≤4.5kb | ≤6kb |
| Expression | Phased expression at medium to high level | Moderately stable expression |
| Expression Duration | Begin to express within 7-14 days, | Begin to express in 2-4 days, |
| Generally 6 months to 24 months | Lasts ≥6 months | |
| Diffusion capacity in vivo | High | Ordinary |
| Immunogenicity | Very low | Low |
| Integration method | Small amount of targeted integration | High frequency random integration |
| Advantages | High yield, simple composition, good safety | Low yield, stable expression |
| Application | Animal experiments | Cell experiments |
Why is AAV the most popular vector in the field of gene therapy?
1. Wide host range: dividing and non-dividing cells;
2. High safety: No pathogenic AAV is found; ITR and rep/cap are expressed on independent plasmids;
3. Low immunogenicity: The immune response to AAV in animals or humans is the smallest among several viral vectors;
4. Good targeting: a variety of serotypes and tissue specificity options.
